TD Cowen Begins Coverage on Certara (NASDAQ:CERT)

Research analysts at TD Cowen started coverage on shares of Certara (NASDAQ:CERT) in a report issued on Thursday, MarketBeat.com reports. The firm set a “buy” rating and a $16.00 price target on the stock. TD Cowen’s target price would indicate a potential upside of 33.56% from the company’s current price.

Several other brokerages also recently issued reports on CERT. Barclays reduced their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Robert W. Baird decreased their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Certara presently has a consensus rating of “Hold” and an average price target of $15.79.

Certara Price Performance

Shares of NASDAQ CERT opened at $11.98 on Thursday. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -59.90, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. The business has a 50 day simple moving average of $12.45 and a 200-day simple moving average of $11.64. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara has a twelve month low of $9.41 and a twelve month high of $19.87.

Hedge Funds Weigh In On Certara

Institutional investors have recently bought and sold shares of the stock. Venturi Wealth Management LLC grew its position in shares of Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock valued at $30,000 after purchasing an additional 2,509 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after acquiring an additional 1,047 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Certara by 112.3% in the 3rd quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock worth $46,000 after acquiring an additional 2,076 shares during the period. Johnson Financial Group Inc. acquired a new stake in shares of Certara during the 4th quarter worth approximately $47,000. Finally, KBC Group NV raised its stake in shares of Certara by 48.2% in the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after purchasing an additional 1,584 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.